Navigation Links
Imugene and Merial Establish Strategic Alliance
Date:12/30/2008

DULUTH, Ga., Dec. 30 /PRNewswire/ -- Merial, a world leading animal health company, and the Australian company Imugene have signed a comprehensive agreement allowing Merial to obtain exclusive rights to Imugene vector technology. Under the Strategic Alliance, Merial will progress candidates through the product development process to global sales. Additional vaccine candidates will be evaluated for proof of concept and, if successful, will also progress into the product development process.

The Strategic Alliance commences December 31st, 2008. Imugene has received an initial payment for future research and the reimbursement of past research fees.

The terms of the Strategic Alliance include the Poultry Productivity Enhancer previously sublicensed to Merial. This vaccine candidate will now be progressed with other FAV (Fowl Adeno Virus) and PAV (Porcine Adeno Virus) vectored vaccine candidates already researched by Imugene and additional vaccine candidates to be disclosed by Merial.

Commenting on the successful conclusion of the exclusive strategic alliance negotiations, Imugene Managing Director Dr. Warwick Lamb said, "The results from our recent trials and vaccine development activities have been significant and have led to the alliance arrangements with one of the world's leading animal health companies. Merial and Imugene will now collaborate over the coming years to develop of a suite of vaccines for worldwide sales."

"We are very pleased to enter this new phase of our relationship with Imugene," said Bob Nordgren, Global Head of Merial Biologicals. "This exclusive strategic alliance and licensing agreement gives Merial access to important technology for our innovation of new approaches that could allow our veterinarian customers innovative means for managing important, poorly controlled diseases of swine and poultry. Our relationship dates back to the very beginning of Imugene as a company, and we are confident that Imugene's adenoviral vectors have significant commercial potential for driving the development of important new products in animal health."

About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs more than 5,400 people and operates in more than 150 countries worldwide. Its 2007 sales were nearly $2.5 billion. Merial Limited is a joint venture between Merck & Co., Inc. and sanofi-aventis. For more information, please see www.merial.com

About Imugene

Imugene Limited (ASX Code: IMU) specialises in the development and commercialisation of novel animal health products for pigs and poultry. Founded in 2002, Imugene has a stable specialist management and scientific team supplemented with extensive use of specialist consultants and contracted trial facilities in the USA and Australia.

Imugene's range of products under development includes vaccines to prevent important livestock diseases and productivity enhancers to improve the economics of raising commercial livestock. These biologically-based vaccines improve the health and welfare of pigs and poultry and reduce or eliminate the use of antibiotics, chemicals and drugs.

Imugene owns the worldwide rights to the Fowl Adenoviral Vector Delivery System for poultry and the Porcine Adenoviral Vector Delivery System for pigs.

For more information please visit the Imugene website www.imugene.com


'/>"/>
SOURCE Merial
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
2. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
3. Environmental Power Corporation and Organix, Inc. Establish Alliance to Produce High Value Soil Amendment Products
4. Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health
5. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
6. Facet Solutions Establishes Corporate Headquarters and Expands Executive Team
7. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
8. Medical Policy Guideline for Trofile(TM) Established By Wellpoint, Inc.
9. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
10. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
11. CSCs DVC Wins $32.3 Million NIAID Contract to Establish Phase 1 Clinical Trial Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... ... taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding ... know someone who suffers from hay fever, urticaria, asthma, atopic eczema or a ...
(Date:6/22/2017)... of Prussia, PA (PRWEB) , ... June 22, ... ... industry knowledge and superior results to clients throughout the biopharma and life sciences ... rapid changes the industry is seeing. Tunnell’s Kip Wolf will be speaking on ...
(Date:6/22/2017)... Lawrence, MA (PRWEB) , ... June 22, 2017 , ... ... completed ILVO validation. The AMPH test was determined to be appropriate as a screening ... for visual interpretation, on the Charm EZ system, and the Charm EZ Lite system. ...
(Date:6/20/2017)... ... June 20, 2017 , ... HorizonScan is providing food and ... most likely threat to their products at the annual IFT conference in Las ... food expo attracts over 20,000 attendees representing food science professionals from over 90 ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
Breaking Biology News(10 mins):